Welcome to our dedicated page for Cytek Biosciences SEC filings (Ticker: CTKB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cytek Biosciences, Inc. filings document the reporting, governance, and security structure of a Nasdaq-listed cell analysis solutions company. Its registered security is common stock traded under the CTKB symbol on the Nasdaq Global Select Market.
The company’s 8-K filings furnish financial-results releases, preliminary revenue updates, and related exhibit disclosures under Item 2.02. Proxy and annual meeting filings cover director elections, advisory executive compensation votes, auditor ratification, stockholder voting results, board-class matters, and other governance subjects. Together, these filings describe Cytek’s public-company reporting framework alongside its business in FSP instruments, reagents, software, services, and cell analysis technologies.
Form 3 overview: Cytek Biosciences, Inc. (CTKB) filed an Initial Statement of Beneficial Ownership for newly appointed director Richard Chin covering the reportable event date of 06/18/2025. The filing is required under Section 16(a) to disclose any equity interest held by insiders at the moment they become subject to reporting obligations.
Key disclosure: Table I and Table II are blank and the “Explanation of Responses” section states “No securities are beneficially owned.” Accordingly, Dr. Chin reports zero direct or indirect ownership of Cytek common shares or derivative securities as of the event date.
Governance context: Because Form 3 establishes the baseline from which future changes will be measured, investors can expect subsequent Form 4 filings if and when the director acquires stock or options. The document was signed by attorney-in-fact Valerie Barnett on 06/20/2025.
Cytek Biosciences, Inc. (CTKB) – Form 4 insider filing, 20 Jun 2025
Director Deborah J. Neff reported two equity awards granted on 18 Jun 2025 as part of routine board compensation.
- Restricted Stock Units (RSUs): 43,973 units, each convertible into one share of common stock. Vesting: 100 % vests on the earlier of 18 Jun 2026 or the company’s 2026 annual shareholder meeting (if held in June 2026). Until vesting, the units remain contingent and non-transferable.
- Non-qualified Stock Options: 23,809 options with an exercise price of $3.07 per share. Vesting mirrors the RSUs—100 % on the earlier of 18 Jun 2026 or the 2026 annual meeting—and the options expire on 18 Jun 2035, giving a 10-year life after vesting.
Both awards are recorded as “A” (acquired) transactions, increasing the director’s derivative holdings to 43,973 RSUs and 23,809 options. No common-stock sales or purchases were disclosed, and no non-derivative ownership changes were reported.
Because the combined 67,782 potentially issuable shares represent a very small fraction of Cytek’s total shares outstanding, the filing is primarily informational and typical for board-level equity incentives. The grant reinforces alignment between the director and shareholders but does not, on its own, alter the company’s capital structure or financial outlook.
Cytek Biosciences, Inc. (CTKB) – Form 4 filing dated 06/20/2025
The filing discloses new equity awards granted to director Jack Ball on 06/18/2025. Two separate instruments were reported:
- Restricted Stock Units (RSUs): 43,973 units, each convertible into one common share. 100 % of the award vests on the earlier of 18 Jun 2026 or the company’s 2026 annual meeting (if held in June 2026). Upon vesting, Ball will receive an equivalent number of common shares.
- Non-qualified Stock Option: Right to purchase 23,809 common shares at an exercise price of $3.07 per share. The option follows the same vesting schedule as the RSUs and carries an expiration date of 18 Jun 2035.
Following these grants, Ball’s directly held derivative positions now include the 43,973 RSUs and 23,809 options; no indirect ownership was reported. The filing does not indicate any sale or disposition of existing shares, and no Rule 10b5-1 trading plan box was checked.
The awards represent routine director compensation and do not provide quantitative information on Cytek’s overall share count, dilution impact, or financial performance. No earnings data, cash payments, or other material corporate actions accompany the disclosure.
Form 4 snapshot: On 18 June 2025 Cytek Biosciences (CTKB) reported that director Michael Holder received two equity awards – 43,973 Restricted Stock Units (RSUs) and 23,809 non-qualified stock options – both coded “A” for acquisition.
Key terms:
- RSUs: One RSU converts into one common share; no cash paid.
- Options: Exercise price set at $3.07, indicating the share price on grant date.
- Vesting for both awards: 100% on the earlier of 18 June 2026 or the 2026 annual meeting (if held in June 2026).
Post-transaction ownership: Holder now directly holds 43,973 RSUs and 23,809 options, representing a potential 67,782 new shares if fully vested and exercised. No sales, dispositions or open-market purchases were disclosed.
Investor takeaway: The filing reflects routine board compensation, aligns the director’s interests with shareholders for at least the next year and introduces only minor potential dilution relative to the company’s total shares outstanding. No information affecting earnings, cash flow or strategy was provided.